Page last updated: 2024-12-07
mdl-201112
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-(6-amino-9H-purin-9-yl)-cyclopentanol: structure given in first source; a synthetic carbocyclic adenosine analog; RN given refers to (1R-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 132408 |
CHEMBL ID | 316207 |
SCHEMBL ID | 4351091 |
MeSH ID | M0218975 |
Synonyms (14)
Synonym |
---|
cyclopentanol, 3-(6-amino-9h-purin-9-yl)-, (1r-cis)- |
9-(cis-cyclopentan-3-ol)adenine |
142130-73-2 |
3-(6-amino-9h-purin-9-yl)-cyclopentanol |
mdl-201112 |
mdl 201449a |
SCHEMBL4351091 |
(1r,3s)-3-(6-aminopurin-9-yl)cyclopentan-1-ol |
CHEMBL316207 |
(1r,3s)-3-(6-amino-9h-purin-9-yl)cyclopentan-1-ol |
mdl201112 |
DTXSID80931363 |
3-(6-amino-9h-purin-9-yl)cyclopentan-1-ol |
(1r,3s)-3-(6-amino-9h-purin-9-yl)cyclopentanol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID90492 | in vitro inhibitory activity was measured against interleukin-1-beta (IL1-beta) production | 1996 | Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13 | Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. |
AID90493 | in vitro inhibitory activity was measured against interleukin-6 (IL-6) production | 1996 | Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13 | Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. |
AID124148 | Protective effects against lethal injections of D-galactosamine sensitized Lipopolysaccharide challenged (LD100) CF1 mice (100 mg/kg IP in PBS) | 1996 | Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13 | Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. |
AID90490 | In vitro inhibitory activity was measured against tumor necrosis factor-alpha production | 1996 | Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13 | Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. |
AID123988 | D-galactosamine sensitized mice were given 3 times the LD100 dose of LPS (100 mg/kg IP in PBS) | 1996 | Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13 | Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl)adenines. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (60.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.80) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |